R. Hindritiani, Felly Nazlia, Nadia Octavia, Trustia Rizqandaru, D. Puspitosari, K. Ruchiatan
{"title":"4%烟酰胺和4%曲酸乳膏与4%对苯二酚乳膏联合治疗表皮黄褐斑的疗效和安全性对比研究","authors":"R. Hindritiani, Felly Nazlia, Nadia Octavia, Trustia Rizqandaru, D. Puspitosari, K. Ruchiatan","doi":"10.20473/bikk.v35.2.2023.93-99","DOIUrl":null,"url":null,"abstract":"Background: Melasma is a hyperpigmentation disorder that affects the quality of life, especially in women. Hydroquinone has remained the mainstay of melasma treatment. However, its safety for long-term usage became a great concern. Combination therapy, such as niacinamide and kojic acid, can be used as an alternative melasma treatment due to different mechanisms of action and synergism. Purpose: The aim of this study was to compare the efficacy and safety of a combination of 4% niacinamide and 4% kojic acid (N-K) vs. 4% hydroquinone (HQ) in epidermal melasma. Methods: This was a randomized, double blind, clinical study on 13 female epidermal melasma patients at the Cosmetic Dermatology Outpatient Clinic of Dr. Hasan Sadikin Hospital, Bandung. Patients received two creams, a combination of N-K and HQ, for split-face therapy, regardless of the sides of the face. All patients were followed up at 4 and 8 weeks. The clinical efficacy was assessed for skin lightening effects using a spectrophotometer (L* value) and the melasma area severity index (MASI). Adverse effects were assessed in all patients. Result: Both the N-K and HQ groups showed significant improvement in skin lightening and MASI scores on week 8 (p <0.05). There was no statistically significant difference in efficacy between the N-K and HQ groups (p >0.05). None of the patients in the N-K group complained of any adverse effects. Whereas in the HQ group, 23.07% presented with pruritus and mild erythema.","PeriodicalId":8792,"journal":{"name":"Berkala Ilmu Kesehatan Kulit dan Kelamin","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Split-Face Comparative Study in Efficacy and Safety between the Combination of 4% Niacinamide and 4% Kojic Acid Cream versus 4% Hydroquinone Cream for Epidermal Melasma\",\"authors\":\"R. Hindritiani, Felly Nazlia, Nadia Octavia, Trustia Rizqandaru, D. Puspitosari, K. Ruchiatan\",\"doi\":\"10.20473/bikk.v35.2.2023.93-99\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Background: Melasma is a hyperpigmentation disorder that affects the quality of life, especially in women. Hydroquinone has remained the mainstay of melasma treatment. However, its safety for long-term usage became a great concern. Combination therapy, such as niacinamide and kojic acid, can be used as an alternative melasma treatment due to different mechanisms of action and synergism. Purpose: The aim of this study was to compare the efficacy and safety of a combination of 4% niacinamide and 4% kojic acid (N-K) vs. 4% hydroquinone (HQ) in epidermal melasma. Methods: This was a randomized, double blind, clinical study on 13 female epidermal melasma patients at the Cosmetic Dermatology Outpatient Clinic of Dr. Hasan Sadikin Hospital, Bandung. Patients received two creams, a combination of N-K and HQ, for split-face therapy, regardless of the sides of the face. All patients were followed up at 4 and 8 weeks. The clinical efficacy was assessed for skin lightening effects using a spectrophotometer (L* value) and the melasma area severity index (MASI). Adverse effects were assessed in all patients. Result: Both the N-K and HQ groups showed significant improvement in skin lightening and MASI scores on week 8 (p <0.05). There was no statistically significant difference in efficacy between the N-K and HQ groups (p >0.05). None of the patients in the N-K group complained of any adverse effects. Whereas in the HQ group, 23.07% presented with pruritus and mild erythema.\",\"PeriodicalId\":8792,\"journal\":{\"name\":\"Berkala Ilmu Kesehatan Kulit dan Kelamin\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-07-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Berkala Ilmu Kesehatan Kulit dan Kelamin\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.20473/bikk.v35.2.2023.93-99\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Berkala Ilmu Kesehatan Kulit dan Kelamin","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.20473/bikk.v35.2.2023.93-99","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
A Split-Face Comparative Study in Efficacy and Safety between the Combination of 4% Niacinamide and 4% Kojic Acid Cream versus 4% Hydroquinone Cream for Epidermal Melasma
Background: Melasma is a hyperpigmentation disorder that affects the quality of life, especially in women. Hydroquinone has remained the mainstay of melasma treatment. However, its safety for long-term usage became a great concern. Combination therapy, such as niacinamide and kojic acid, can be used as an alternative melasma treatment due to different mechanisms of action and synergism. Purpose: The aim of this study was to compare the efficacy and safety of a combination of 4% niacinamide and 4% kojic acid (N-K) vs. 4% hydroquinone (HQ) in epidermal melasma. Methods: This was a randomized, double blind, clinical study on 13 female epidermal melasma patients at the Cosmetic Dermatology Outpatient Clinic of Dr. Hasan Sadikin Hospital, Bandung. Patients received two creams, a combination of N-K and HQ, for split-face therapy, regardless of the sides of the face. All patients were followed up at 4 and 8 weeks. The clinical efficacy was assessed for skin lightening effects using a spectrophotometer (L* value) and the melasma area severity index (MASI). Adverse effects were assessed in all patients. Result: Both the N-K and HQ groups showed significant improvement in skin lightening and MASI scores on week 8 (p <0.05). There was no statistically significant difference in efficacy between the N-K and HQ groups (p >0.05). None of the patients in the N-K group complained of any adverse effects. Whereas in the HQ group, 23.07% presented with pruritus and mild erythema.